Sperl, J. Et Al. 2016. Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. JOURNAL OF HEPATOLOGY , vol.65, no.6 , 1112-1119.

Sperl, J., Horvath, G., Halota, W., Arenas Ruiz-Tapiador, J., Streinu-Cercel, A., Jancoriene, L., ... Werling, K.(2016). Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. JOURNAL OF HEPATOLOGY , vol.65, no.6, 1112-1119.

Sperl, Jan Et Al. "Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial," JOURNAL OF HEPATOLOGY , vol.65, no.6, 1112-1119, 2016

Sperl, Jan Et Al. "Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial." JOURNAL OF HEPATOLOGY , vol.65, no.6, pp.1112-1119, 2016

Sperl, J. Et Al. (2016) . "Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial." JOURNAL OF HEPATOLOGY , vol.65, no.6, pp.1112-1119.

@article{article, author={Jan Sperl Et Al. }, title={Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial}, journal={JOURNAL OF HEPATOLOGY}, year=2016, pages={1112-1119} }